# Intellia Therapeutics

Type: Company (NTLA)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/intellia-therapeutics
Canonical HTML page: https://getfinancebrief.com/entity/intellia-therapeutics

## Recent coverage (1 stories)

### Payoneer Leads Mid-Cap Earnings Surge as B2B Resilience Offsets Macro Volatility
2026-02-26 22:38:34 · Sentiment: Neutral · Impact: 5/10 · Sources: 12

Payoneer reported robust Q4 2025 results, driven by double-digit growth in B2B volume and strategic expansion into emerging markets. The broader mid-cap landscape shows a divergence between high-growth consumer brands like Celsius and R&D-heavy biotech firms navigating a complex regulatory environment.
Full story: https://getfinancebrief.com/story/payoneer-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.